Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: A multicentre, randomized study

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 8, 2010, Pages 744-749

  Pérez De Llano, Luis A ^a   Leiro Fernández, Virginia ^b   Golpe, Rafael ^a   Núñez Delgado, Jose M ^c   Palacios Bartolomé, Ana ^d   Méndez Marote, Lidia ^a   Colomé Nafria, Esteve ^e  

^a HOSPITAL XERAL CALDE   (Spain)

^b HOSPITAL XERAL CÍES   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d Hospital Clinico Universitario   (Spain)

^e Laboratorios LEO Pharma SA   (Spain)

Author keywords

cost analysis; long term; low molecular weight heparin; pulmonary embolism; venous thromboembolism; vitamin K antagonist

Indexed keywords

ACENOCOUMAROL; TINZAPARIN;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPISTAXIS; FEMALE; GINGIVITIS; HEALTH CARE UTILIZATION; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METRORRHAGIA; MULTICENTER STUDY; PLEURAL HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RESPIRATORY TRACT HEMORRHAGE; SECONDARY PREVENTION; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ACENOCOUMAROL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 78349251688     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283401406     Document Type: Article

References (26)

1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (Suppl 6):454S-545S. (Pubitemid 351892971)
2. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003; 1:1906-1913.
3. Van der Heijden JF, Hutten BA, Büller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002:CD002001.
4. Hull RD, Raskob GE, Brant RF, Mah AF, Burke N, Dear R, et al. Self-management long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120:72-82.
5. Romera A, Cairols MA, Vila-Coll R, Mart́i X, Colomé E, Bonell A, et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009; 37:349-356.
6. White RH, Zhou H, Murin S, Harvey D. Effectofethnicityand genderon the incidence ofvenousthromboembolism in adiverse population in California in 1996. Thromb Haemost 2005; 93:298-305.
7. Jiménez D, D́iaz G, Marín E, Vidal R, Sueiro A, Yusen RD. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost2006; 95:562-566.
8. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated pulmonary embolism. JAMA 1998; 279:458-462. (Pubitemid 28082257)
9. Beckman JA, Dunn K, Sasahara AA, Goldhaber SZ. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost 2003; 89:953-958.
10. Kucher N, Quiroz R, McKean S, Sasahara AA, Goldhaber SZ. Extended enoxaparin monotherapyforacutesymptomatic pulmonary embolism. Vasc Med 2005; 10:251-256.
11. Donzé J, Le Gal G, Fine MJ, Roy PM, Sánchez O, Verschuren F, et al. Prospective validation of the Pulmonary Embolism Severity Index. Aclinical prognostic model for pulmonary embolism. Thromb Haemost 2008; 100:943-948.
12. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130:1390-1396.
13. Vademecum International. www.vademecum.medicom.es; 2008
14. Health Costs Database eSalud. http://www.oblikue.com/bddcostes/.
15. Decree 164/2008, of 17 of July, establishing the tariffs of the Health Services offered by the centres depended on the Galician Health System. Diario Oficial de Galicia 2008 (No 150):15060-15074. http://gomezcordoba.com/ documentos/concursos/PUNTUACI%D3N%20DEFINITIVA%20GALICIA.pdf/.
16. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. N Engl J Med 1997; 337:663-669.
17. Montes Santiago J, Rey Garćia G, Mediero Doḿinguez A. Pulmonary embolism in medical inpatients. An approach to trends and costs in Spain. Ann Med Interna 2004; 21:326-330.
18. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med2004; 140:175-183.
19. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695-1702.
20. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357:1094-1104.
21. Working Group of the Venous Thromboembolism in Spain. Sociedad Española de Medicina Interna ed. Madrid 2006.
22. Montes J, González L, Amador L, Novo A, Enero M, Rey G, et al. Home versus inpatient therapy for deep venous thrombosis. A cost-comparative analysis. Ann Med Interna 2005; 22:369-372.
23. Castro DJ, D́iaz G, Mart́i D, Escobar C, Ortega J, Garćia-Rull S, et al. Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism. Blood Coagul Fibrinolysis 2007; 18:173-177.
24. Instituto Gallego de Estad́istica. Galician population in 2008. http://www.ige.eu/web/mostrar-actividade-estatistica.jsp?idioma=gl&codigo= 0201001002.
25. Lissovoy G, Yusen RD, Spiro TE, Krupski WC, Champion AH, Sorensen SV. Cost for inpatient care of venous thrombosis. A trial of Enoxaparin vs. Standard Heparin. Arch Intern Med 2000; 160:3160-3165.
26. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001; 111:130-139.